The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial
Background: Breast cancer and its treatments are associated with a detrimental effect on bone health. Here we report the results of an exploratory analysis assessing changes in levels of biomarkers of bone metabolism in patients enrolled in the phase IIIb 4EVER study. Methods: The 4EVER trial invest...
Main Authors: | Peyman Hadji, Oliver Stoetzer, Thomas Decker, Christian M. Kurbacher, Frederik Marmé, Andreas Schneeweiss, Christoph Mundhenke, Andrea Distelrath, Peter A. Fasching, Michael P. Lux, Diana Lüftner, Wolfgang Janni, Mathias Muth, Julia Kreuzeder, Claudia Quiering, Eva-Marie Grischke, Hans Tesch |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-02-01
|
Series: | Journal of Bone Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137418301131 |
Similar Items
-
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
by: Claudia Omarini, et al.
Published: (2018-01-01) -
Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2
by: Gabriel N. Hortobagyi
Published: (2015-03-01) -
The Roles of Minocycline, Rapamycin, and Everolimus in Kainic acid-induced Seizure
by: Yi-Chin Lin, et al.
Published: (2015) -
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
by: Mariya Rozenblit, et al.
Published: (2021-01-01) -
Exemestane in the prevention setting
by: Jennifer Keating Litton, et al.
Published: (2012-05-01)